Oligodendroglioma medical therapy
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]Sujit Routray, M.D. [3]
Overview
Overview
The predominant therapy for oligodendroglioma is surgical resection. Adjunctive chemotherapy and radiation are required. Supportive therapy for oligodendroglioma includes anticonvulsants and corticosteroids.
Medical Therapy
Medical Therapy
Innovative treatment options:
- Brain tumors can be complex and require a combination of treatments for the best outcome.
- There is quite a wide range of treatments to meet the individual needs of each patient which includes standard therapies, precision medicine and clinical trials.
- Some of them are listed below:
- Brachytherapy:
- Destroys tumors by implanting radioactive medicine directly to or near the treatment site.
- Chemotherapy:
- Reaches cancer that may have spread, even microscopically, throughout the body.
- Craniotomy:
- Intensity-modulated radiation therapy:
- Minimally invasive cranial base surgery:
- Uses smaller incisions and specially designed instruments to eliminate a tumor while saving the surrounding tissue from damage.
- Stereotactic radiosurgery & radiotherapy:
- Brachytherapy:
The medical therapy for oligodendroglioma includes:
Radiotherapy
- Post-operative radiotherapy is recommended among all patients who develop oligodendroglioma.[1][2]
- Radiotherapy may not cure the cancer but it can:
- Control the tumor
- Delay recurrence
- Increase survival
- External beam radiation therapy is preferred to whole brain radiotherapy.[1]
- External beam radiation therapy is usually administered in standard fractions of 1.8–2 Gy and can reach a total dose of 60 Gy.[3]
Chemotherapy
- Chemotherapy is indicated as adjuvant therapy for oligodendroglioma.[1][4][5][6][7]
- Oligodendroglioma responds better to chemotherapy than astrocytoma of comparable grade.[8]
- Oligodendroglioma is the most chemosensitive of all the glial tumors.[9]
- Symptomatic, aggressive, enlarging, enhancing, and non-anaplastic oligodendrogliomas respond better to chemotherapy.[10]
- Temozolomide (Temodar) is the preferred drug for the treatment of oligodendroglioma.[1]
- PCV 3 regimen is the preferred combination chemotherapy for anaplastic oligodendroglioma which includes the following dosing schedule:[1][11]
- CCNU is administered on day 1
- Procarbazine is administered daily for 14 days beginning on day 8
- Vincristine is administered on days 8 and 29 of each 6-week cycle of therapy[12]
- Other chemotherapeutic drugs that may be used for the treatment of oligodendroglioma include:[13][9]
- If oligodendroglioma is unresponsive to the chemotherapeutic drugs used in earlier treatments or if it recurs, other drugs that may be used include:[13]
Supportive treatment
- Supportive therapy for oligodendroglioma focuses on relieving symptoms and improving the patient’s neurologic function and includes:[1]
- Anticonvulsants:
- Anticonvulsants are administered to the patients who have a seizure
- Phenytoin given concurrently with radiation may have serious skin reactions such as:
- Corticosteroids:
- Usually dexamethasone is given 4-10 mg every 4-6 h, which leads to:
- Reduced peritumoral edema
- Diminished mass effect
- Lower intracranial pressure with a decrease in symptoms (headache or drowsiness)
- Usually dexamethasone is given 4-10 mg every 4-6 h, which leads to:
References
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Treatment of oligodendroglioma. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/oligodendroglioma/?region=on
- ↑ Harat M, Blok M, Harat A, Soszyńska K (2019). “The impact of adjuvant radiotherapy on molecular prognostic markers in gliomas”. Onco Targets Ther. 12: 2215–2224. doi:10.2147/OTT.S200818. PMC 6441459. PMID 30988626.
- ↑ Stupp R, Tonn JC, Brada M, Pentheroudakis G, ESMO Guidelines Working Group (2010). “High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Ann Oncol. 21 Suppl 5: v190–3. doi:10.1093/annonc/mdq187. PMID 20555079.
- ↑ Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR; et al. (1998). “Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas”. J Natl Cancer Inst. 90 (19): 1473–9. PMID 9776413.
- ↑ Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J; et al. (2013). “Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402”. J Clin Oncol. 31 (3): 337–43. doi:10.1200/JCO.2012.43.2674. PMC 3732012. PMID 23071247.
- ↑ van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY; et al. (2013). “Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951”. J Clin Oncol. 31 (3): 344–50. doi:10.1200/JCO.2012.43.2229. PMID 23071237.
- ↑ Mohammad F, Weissmann S, Leblanc B, Pandey DP, Højfeldt JW, Comet I; et al. (2017). “EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas”. Nat Med. 23 (4): 483–492. doi:10.1038/nm.4293. PMID 28263309.
- ↑ Schmoldt A, Benthe HF, Haberland G (1975). “Digitoxin metabolism by rat liver microsomes”. Biochem Pharmacol. 24 (17): 1639–41. PMID doi:10.1016/S0090-3019(03)00167-8 Check
|pmid=value (help). - ↑ 9.0 9.1 Cairncross JG, Macdonald DR (1988). “Successful chemotherapy for recurrent malignant oligodendroglioma”. Ann Neurol. 23 (4): 360–4. doi:10.1002/ana.410230408. PMID 3382171.
- ↑ Cairncross JG, Macdonald DR, Ramsay DA (1992). “Aggressive oligodendroglioma: a chemosensitive tumor”. Neurosurgery. 31 (1): 78–82. PMID 1641113.
- ↑ Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J; et al. (2002). “Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets”. Am J Pathol. 161 (1): 313–9. doi:10.1016/S0002-9440(10)64183-1. PMC 1850690. PMID 12107116.
- ↑ Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ; et al. (1980). “Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors”. Cancer Treat Rep. 64 (2–3): 237–44. PMID 7407756.
- ↑ 13.0 13.1 Chemotherapeutic drugs in malignant gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/treatment/chemotherapy/?region=on
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
